Trial reportNeurogastroenterology and motility2011
Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome.
Trial report in Neurogastroenterology and motility, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.BMJ open gastroenterology · 2023Trial
- Trial
- Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation.Contemporary clinical trials communications · 2022Article
- Recent advances in understanding and managing chronic constipation.F1000Research · 2018Review
- New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.World journal of gastroenterology · 2017Review
- Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.Current gastroenterology reports · 2017Review
- Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Journal of neurogastroenterology and motility · 2016Article
- Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment.F1000Research · 2016Review
- Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation.Caspian journal of internal medicine · 2016Article
- New Options in Constipation Management.Current oncology reports · 2015Review
- Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P.World journal of gastroenterology · 2015Article
- Rectal tone and compliance affected in patients with fecal incontinence after fistulotomy.World journal of gastroenterology · 2015Observational
- Management Strategies for Abdominal Bloating and Distension.Gastroenterology & hepatology · 2014Article
- The use of non-narcotic pain medication in pediatric gastroenterology.Paediatric drugs · 2014Review
- Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.World journal of gastroenterology · 2014Review
- Open channels for functional bowel disorders: guanylate cyclase C agonists in IBS and CC.Digestive diseases and sciences · 2013Article
- Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.BMC pharmacology · 2012Article
- Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation.Clinical medicine insights. Gastroenterology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIn clinical trials, lubiprostone reduced the severity of abdominal pain. The primary aim was to determine whether lubiprostone raises the threshold for abdominal pain induced by intraluminal balloon distention. A secondary aim was to determine whether changes in pain sensitivity influence clinical pain independently of changes in transit time.
methodsSixty-two patients with irritable bowel syndrome with constipation (IBS-C) participated in an 8-week cross-over study. All subjects completed a 14-day baseline ending with a barostat test of pain and urge sensory thresholds. Half, randomly selected, then received 48 μg day(-1) of lubiprostone for 14 days ending with a pain sensitivity test and a Sitzmark test of transit time. This was followed by a 14-day washout and then a crossover to 14 days of placebo with tests of pain sensitivity and transit time. The other half of the subjects received placebo before lubiprostone. All kept symptom diaries. KEY
resultsStools were significantly softer when taking lubiprostone compared to placebo (Bristol Stool scores 4.20 vs 3.44, P < 0.001). However, thresholds for pain (17.36 vs 17.83 mmHg, lubiprostone vs placebo) and urgency to defecate (14.14 vs 14.53 mmHg) were not affected by lubiprostone. Transit time was not significantly different between lubiprostone and placebo (51.27 vs 51.81 h), and neither pain sensitivity nor transit time was a significant predictor of clinical pain. CONCLUSIONS & INFERENCES: Lubiprostone has no effect on visceral sensory thresholds. The reductions in clinical pain that occur while taking lubiprostone appear to be secondary to changes in stool consistency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.